Surgical treatment outcome of giant cell tumor of distal ulna: En bloc resection vs. curettage and bone graft

Outcomes of metatarsal Ewing sarcoma following the resection and intercalary reconstruction with fibular strut allograft: A retrospective case series

BACKGROUND

Traditionally, metatarsal Ewing sarcoma (ES) is managed with disarticulation above the tarsometatarsal joint and ray amputation. In this study, we evaluate the outcomes of a less invasive approach in patients with metatarsal ES and good response to neoadjuvant chemotherapy.

METHODS

Eleven patients with metatarsal ES (mean age: 11.5 ± 3) and complete radiologic response to neoadjuvant chemotherapy who underwent resection and reconstruction with fibular strut allograft were included.

RESULTS

At a mean follow-up of 8.5 ± 4 years, the mean Musculoskeletal Tumor Society (MSTS) score of the patients was 29 ± 1.7. Patients with metatarsophalangeal joint fusion had limitations in reactional activities. One patient had a local recurrence. Postoperative complications included wound dehiscence (n = 1), superficial infection (n = 1), and allograft fracture (n = 1). Only one patient required revision surgery.

CONCLUSION

Fibular allograft reconstruction after resection of metatarsal ES can be regarded as a valuable alternative to amputation in patients who respond well to neoadjuvant chemotherapy.

LEVEL OF EVIDENCE

IV.

Clinical Outcomes of Curettage versus Surgical Resection of Giant Cell Tumor of the Distal Radius - A Systematic Review and Meta-analysis

Objective  Surgical procedures of curettage and surgical resection are used to treat giant cell tumor (GCT) of the distal radius, but it is still controversial whether one provides better functional outcomes than the other. The present study aims to determine and compare both procedures regarding complications, local recurrence, and mobility. Methods  A complete search of the applicable literature was done and independently assessed by three authors. Included studies reported on patients who were surgically treated for GCT of the distal radius with either curettage or surgical resection. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was used to obtain research regarding outcomes of surgical resection and curettage for GCT of the distal radius. A meta-analysis was performed using this data. Quality assessment was performed. Results  Seven studies, comprising 114 patients with resection and 108 with curettage, totaling 222 subjects with 117 males and 105 females, were included in the present review. Overall, patients in the curettage group had a higher recurrence rate (0.205; 95% confidence interval [95%CI] = 0.057-0.735; p  = 0.015). Incidences in complications remains the same in both groups (2.845; 95%CI = 0.644-12.57; p  = 0.168). Incidences in functional outcomes were the same in both groups as well (-0.948; 95%CI = -2.074-0.178; p  = 0.099). Conclusion  The authors prefer resection and reconstruction for GCT of distal radius as optimum treatment method due to the similar functional outcomes and lower chances of recurrence. Curettage might be a treatment option in low-grade GCT coupled with adjuvant, neoadjuvant or ablation to reduce the risk of recurrence.

Giant cell tumors of the distal ulna: long-term recurrence rate and functional outcomes of en bloc resection versus curettage in a multicenter study

OBJECTIVE

The wrist is the second most commonly involved location for GCTB, while distal ulna is a relatively rare location and limited evidence exists on which surgical approaches and reconstruction techniques are optimal. We carried out a multicenter retrospective study to evaluate the recurrence rate of distal ulna GCTB and the long-term functional outcomes of different surgery options.

METHODS

All 28 patients received surgical treatment for distal ulna GCTB in one of three tertiary bone tumor centers between May 2007 and January 2021 with a minimum two-year follow-up. Surgical options included intralesional curettage or en bloc resection (one of 3 types). Functional outcomes were assessed by the MSTS score, the QuickDASH instrument, MWS, and MHQ according to the latest treatment.

RESULTS

Overall recurrence rate was 14.2%. The curettage group (N = 7) had a significantly higher recurrence rate compared to en bloc resection (N = 21) (42.9% vs 4.8%) (mean follow-up: 88.8 mo). Seven patients received the Darrach procedure, 5 received the original Sauvé-Kapandji procedure, and 9 received the modified Sauvé-Kapandji procedure with extensor carpi ulnaris (ECU) tenodesis. Of the 4 patients having a recurrence, 1 received the Darrach EBR, 2 received the modified Sauvé-Kapandji procedure, and 1 received resection for soft tissue recurrence. Only MWS and esthetics in the MHQ scores were different (curettage, Darrach, Sauvé-Kapandji, and Sauvé-Kapandji with ECU tenodesis [MWS: 96.5 ± 1.3 vs 91.5 ± 4.7 vs 90.8 ± 2.8 vs 91.5 ± 3.6; esthetics in MHQ: 98.5 ± 3.1 vs 89.9 ± 4.7 vs 93.8 ± 4.4 vs 92.6 ± 3.8], respectively).

CONCLUSIONS

En bloc resection for distal ulna GCTB had a significantly lower recurrence rate compared with curettage and achieved favorable functional outcome scores. Given the higher recurrence rate after curettage, patients should be well informed of the potential benefits and risks of selecting the distal radioulnar joint-preserving procedure. Moreover, reconstructions after tumor resection of the ulna head do not appear to be necessary.

Giant Cell Tumor in the Distal End of the Ulna Managed by Darrach's Procedure: A Case Report

Giant cell tumors (GCTs) are rare, benign, and locally invasive tumors, typically found in the epiphysis of long bones, most commonly at the distal femur and proximal tibia. To date, GCTs of the distal end of the ulna have been very rare. We document a case of a 38-year-old female with a distal ulna GCT, managed with en-bloc resection of the tumor with flexor carpi ulnaris and extensor carpi ulnaris tendon stabilization. The main aim of the GCT treatment is to prevent local recurrence and to maintain the function of the limb. Physical therapy was also given to the patient which helped in relieving pain, reducing edema, and increasing strength and range of motion. The patient was able to perform activities of daily living with the help of physical therapies and exercises. More research is needed to determine if broad excision of the distal ulna alone is a successful therapy for primary bone cancers affecting the distal ulna, including GCTs.

Treatment of Recurrent Giant Cell Tumor of Bones: A Systematic Review

The giant cell tumor of bones (GCTB) is a benign bone tumor with high postoperative recurrence potential. No specific treatment protocol has been developed to date in case of tumor recurrence, and the kind of re-operative surgery depends upon the surgeon's preferences. The aim of this systematic review is to determine the second recurrence rate and the respective functional results of the available treatment options applied to recurrent GCTB. Medline/PubMed and Scopus were searched to identify articles published until March 2023. Twelve studies fulfilled the inclusion criteria, comprising 458 patients suffering from recurrent GCTB. The overall incidence of second recurrence was 20.5%, at a mean interval of 28.8 months after the first surgery, and it was more evident after intralesional curettage (IC) surgery than en-bloc resection (EBR) (p = 0.012). In the IC group of patients, the second recurrence rate was lower and the functional outcome was greater when polymethylmethacrylate cement (PMMAc) was used as an adjuvant instead of bone grafting (p < 0.001 for both parameters). Reconstruction of the created bone defect after EBR with a structural allograft provided a better outcome than prosthesis (p = 0.028). According to this systematic review, EBR (first choice) and IC with PMMAc (second choice) are the best treatment options for recurrent GCTB.

Recurrent giant cell tumour of the distal ulna after en bloc resection with preoperative denosumab use

In recent years, denosumab has been used to treat giant cell tumour of bone (GCTB) not only in cases where surgery is complicated but also preoperatively to decrease the preoperative grade or to facilitate surgery for Campanacci grade II and III cases. However, there are no clear protocols regarding the preoperative use of denosumab before en bloc resection. There are a few reports of recurrent cases after en bloc resection; however, the association with the use of denosumab is unknown. We present the clinical, radiological and histopathological findings of a case of Campanacci grade III GCTB at the distal end of the ulna, which resulted in soft tissue recurrence after en bloc resection with the preoperative use of denosumab.

[Treatment of giant cell tumor of bone around knee joint with three-dimensional printing personalized prosthesis]

OBJECTIVE

To investigate the short-term effectiveness of three-dimensional (3D) printing personalized prosthesis in the treatment of giant cell tumor of bone around knee joint.

METHODS

A clinical data of 9 patients with giant cell tumor of bone around knee joints and met the inclusive criteria between May 2014 and August 2017 was retrospectively analysed. There were 4 males and 5 females, with an average age of 35.8 years (range, 24-50 years). The lesion located at the distal femur in 4 cases and at the proximal tibia in 5 cases. The disease duration was 5-25 months (mean, 12.9 months). According to Campanacci grading, there were 2 patients of grade Ⅰ and 7 of grade Ⅱ. The 3D printing personalized prosthesis was designed based on the CT scanning and 3D reconstruction prepared before operation. All patients were treated with the tumor resection and 3D printing personalized prosthesis reconstruction. The radiological examination was taken to observe the tumor recurrence and the Musculoskeletal Tumor Society 1993 (MSTS93) score was used to evaluate the knee function.

RESULTS

All operations were successful and all incisions healed by first intention without early complications. All patients were followed up 24-40 months (mean, 31.2 months). At last follow-up, no complication such as pain, pathological fracture, prosthesis loosening, or tumor recurrence occurred. The MSTS93 score was 20-29 (mean, 24.7). The knee function was rated as excellent in 6 cases and good in 3 cases, with the excellent and good rate of 100%.

CONCLUSION

For giant cell tumor of bone around knee joint, 3D printing personalized prosthesis has the advantages of bio-fusion with host bone, mechanical stability, good joint function, and ideal short-term effectiveness. But the middle- and long-term effectiveness still need to be further observed.